

UPDATES AND CHANGING PARADIGMS

in the treatment of

MULTIPLE SCLEROSIS



PRIME®



Monday, October 24, 2016

12:00 ART/11:00AM US ET/8:00AM PT

Friday, October 28, 2016

12:00 BRST/10:00AM US ET/7:00AM PT

Expert Faculty:

Edgardo Cristiano, MD, FAAN

Assistant Professor of Neurology
University Institute of the Hospital Italiano
Head of the Neurological Department
Hospital Italiano de Buenos Aires
University of Buenos Aires
Buenos Aires, Argentina

Suhayl Dhib-Jalbut, MD

Professor and Chairman, Department of Neurology
Rutgers Robert Wood Johnson (RWJ) Medical School
Chief, Neurology Service
RWJ University Hospital
Director, RWJ Center for Multiple Sclerosis
President, ACTRIMS
New Brunswick, NJ

Agenda:

- I. New Insights Into MS Pathophysiology, Diagnostic Approaches, and Novel Therapeutic Mechanisms of Action
- II. Efficacy and Safety of Therapies for Relapsing and Progressive Forms of MS
- III. Advances in Research and Treatment for Relapsing and Progressive MS
- IV. Recognizing When and How to Apply Individualized Treatment

Learning Objectives:

- Differentiate pathophysiological mechanisms, diagnostic procedures, and therapeutic strategies for RRMS versus progressive forms of the disease
- Evaluate recent clinical trial data on the risk-benefit profiles of established and new DMTs through peer-to-peer discussions
- Assess the role and utility of available and emerging therapies for relapsing and progressive forms of MS that act through depleting B cells, sequestering T cells, or promoting neuroprotection or remyelination
- Incorporate evidence to guide effective individualized treatment decision-making for newly diagnosed patients and those not responding adequately or with nonadherence to initial therapies

There is no fee for this CME activity as it is sponsored by PRIME® through an educational grant from F. Hoffman-LaRoche, Ltd.

Intended Audience:

Physicians, Nurses, and the MS Treatment Team

Webinar Overview:

Leveraging the latest findings in multiple sclerosis (MS) pathophysiology, radiology, and therapeutic strategies, leading MS experts explore clinical implications and practical applications of new evidence for the neurology team. Central to these panel discussions, understanding the roles of T cells and B cells in MS pathophysiology and differentiating the benefit/risk profile of new and emerging therapies will provide a foundation for individualized treatment decision-making. Further topics of debate include considerations for switching disease-modifying therapy (DMT) and advances in the treatment and management of patients with progressive MS. Each of these highly interactive webinar sessions will feature 2 internationally renowned MS experts discussing timely topics to meet the needs of neurologists and MS treatment teams.

Accreditation:

PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

Physician Credit Designation Statement

PRIME® designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.



Nurse Accreditation Statement

ANCC PRIME® designates this activity for 1.0 contact hour.



The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.



Register Now:

primeinc.org/ms